Monnier et al. studied dawn phenomenon in three groups of subjects with type 2 diabetes (on diets alone, on insulin sensitizers alone, and on insulin secretagogues alone or in combination with insulin sensitizers) by using CGMS. This evidence concerns the gene INS and type 2 diabetes mellitus.